Interferon-Based Treatment for Patients with Mycosis Fungoides and Hepatitis C Virus Infection: A Case Series
- 137 Downloads
Interferon (IFN) is a treatment option for both mycosis fungoides (MF) and hepatitis C virus (HCV) infection. Chemotherapy and anti-HCV treatment are generally not administered concurrently for fear of overlapping side effects.
Herein, we report on a subset of patients who received IFN-containing therapy for MF and HCV infection simultaneously. We aimed to evaluate whether concomitant treatment for MF and HCV is effective and well tolerated.
We reviewed the records of patients who were seen at MD Anderson Cancer Center from 2008 to 2013 with histologically confirmed MF and chronic HCV infection, and were treated with simultaneous focus on both diseases.
Six HCV-infected patients with MF received simultaneous anti-HCV and anti-MF treatment with IFN-containing therapy. Two patients achieved sustained virological response (regarded as virological cure). They both received antiviral combination therapy with ribavirin. All patients experienced some improvement of their cutaneous lesions, with two of them achieving complete MF remission. All six patients developed side effects while receiving treatment; two of them had grade 4 toxic effects requiring treatment discontinuation.
IFN-based therapy can be administered for MF and HCV infection concurrently to provide not only virological but also oncological benefits to chronically HCV-infected MF patients. However, this regimen is poorly tolerated. Further studies are warranted in this patient population, using different treatment combinations with improved efficacy, safety, and tolerability.
The authors are indebted to Don Norwood for his editorial assistance.
Conflict of Interest Disclosures
Dr. Torres is a consultant for Gilead Sciences, Merck & Co., Inc., Novartis, Astellas, Pfizer, Theravance, Inc., Genentech, and Vertex Pharmaceuticals, and has received research grants from Merck & Co., Inc. and Vertex Pharmaceuticals. Drs. Kyvernitakis, Duvic, and Mahale report no potential conflicts of interest.
No sources of funding were used for conducting this study or preparing this manuscript.
- 7.Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29(18):2598–607.PubMedPubMedCentralCrossRefGoogle Scholar
- 8.Division of AIDS. Division of AIDS table for grading the severity of adult and pediatric adverse events. Bethesda: Division of AIDS; 2004.Google Scholar
- 15.Garcia-Garcia I, Gonzalez-Delgado CA, Valenzuela-Silva CM, et al. Pharmacokinetic and pharmacodynamic comparison of two “pegylated” interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. BMC Pharmacol. 2010;10:15.PubMedPubMedCentralCrossRefGoogle Scholar
- 16.Mahale P, Miller ED, Blechacz B, Herlong HF, Davila M, Torres HA. The effect of antiviral therapy on progression of liver disease in hepatitis C virus-infected patients with malignancies. Hepatology. 2013;58(S4):909A.Google Scholar
- 20.American Association for the Study of Liver Diseases, Infectious Diseases Society of America, International Antiviral Society–USA. Initial treatment of HCV infection in patients starting treatment. Recommendations for testing, managing, and treating hepatitis C. 2014. http://www.hcvguidelines.org. Accessed 27 May 2014.
- 23.Torres HA, Mahale P, Raad II, Kontoyannis DP. Hepatitis C virus infection in patients with cancer: a single-institution experience in 642 patients. Hepatology. 2013;58(S4):1290A.Google Scholar